MAIA Expands THIO-101 Lung Cancer Trial in U.S.

The latest announcement is out from MAIA Biotechnology, Inc. ( (MAIA) ).

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company specializing in targeted immuno-oncology therapies, is developing ateganosine (THIO), a first-in-class telomere-targeting agent for telomerase-positive non-small cell lung cancer patients who have exhausted standard checkpoint inhibitor treatments. The company’s focus on later-line NSCLC and its FDA Fast Track designation underscore its ambition to address a large, underserved population with limited therapeutic options.

On April 16, 2026, MAIA activated the first U.S. clinical site, at Summit Medical Group in New Jersey, for its ongoing international Phase 2 THIO-101 expansion trial evaluating ateganosine as a third-line treatment for advanced non-small cell lung cancer. The U.S. expansion, backed by a $2.3 million NIH grant and following 2025 data showing disease control, response, and survival outcomes well above standard benchmarks with an acceptable safety profile, significantly broadens the patient pool and strengthens MAIA’s position in the competitive NSCLC landscape.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a Chicago-based clinical-stage biopharmaceutical and immuno-oncology company developing targeted therapies for cancer. Its lead program is ateganosine (THIO), a first-in-class telomere-targeting agent in clinical development for non-small cell lung cancer (NSCLC), focused on patients with telomerase-positive cancer cells who have progressed beyond current checkpoint inhibitor regimens.

The company aims to commercialize novel mechanisms of action that meaningfully improve and extend the lives of cancer patients. MAIA holds U.S. FDA Fast Track designation for its lead drug in advanced NSCLC, positioning it to potentially benefit from expedited regulatory review pathways in a setting where treatment options remain limited.

Average Trading Volume: 1,093,999

Technical Sentiment Signal: Sell

Current Market Cap: $86.15M

For a thorough assessment of MAIA stock, go to TipRanks’ Stock Analysis page.